Latest minimal residual disease Stories
Deal Expected to Expedite the Development and Commercialization of Immunosequencing Applications SEATTLE, Jan.
Secondary Analysis Demonstrates 40 Percent of Patients who Achieved Complete Remission Were Enabled to Proceed to Stem Cell Transplant THOUSAND OAKS, Calif., Dec.
- AbbVie Presents for the First Time Results from the Venetoclax Phase 2 Program in Acute Myelogenous Leukemia NORTH CHICAGO, Ill., Dec.
78 Percent of Patients Treated With BLINCYTO Experienced a Complete Minimal Residual Disease (MRD) Response After One Treatment Cycle THOUSAND OAKS, Calif., Dec.
SAN FRANCISCO, Dec.
Data Validates Clinical Advantage of Tracking Minimal Residual Disease with the clonoSEQ(TM) Test in Patients with ALL, CLL, MM, DLBCL SEATTLE, Dec.
First available immunosequencing Kit with validated bias control methodology to ensure data reliability SEATTLE, Nov.
Additional Global Regulatory Filings Reinforce Commitment to Addressing Significant Unmet Needs for Patients With This Aggressive Cancer With Limited Treatment Options THOUSAND OAKS,
Highly distinguished advisory board to strengthen incorporation of Next Generation Sequencing (NGS) into clinical care for patients with blood cancers SEATTLE, Sept.